Diagnostic Tests and Advancements

Diagnostic Tests:

Good science assists diagnosis

Diagnosis of infectious diseases is an imperfect science. The emergence of new diseases and the variable responses of individuals to infection present constant challenges to public health and medicine. Laboratory testing is a vital part of the diagnostic process, contributing objective results which complement clinical findings to help establish the cause of disease.


Our product related to ELISA technologies offers by Gentaur that relies on well-defined antigenic targets for Lyme disease. One such product is the "Lyme Borreliosis IgG ELISA Assay," which is designed for the qualitative detection of IgG antibodies to Borrelia burgdorferi in human serum or plasma. The kit utilizes a 26 amino-acid peptide antigen for the specific and sensitive detection of Lyme disease.

A tick C1q protein alters infectivity of the Lyme disease agent by modulating interferon γ


A new generation of ELISAs is often based on advancements in technology and methodology. Some key areas of innovation include:

  1. Multiplexing: Allowing the detection of multiple analytes in a single assay, saving time and resources.
  2. Automation: Improving efficiency and reducing human error in the assay process.
  3. High-throughput screening: Enabling the analysis of a large number of samples simultaneously.
  4. Enhanced sensitivity and specificity: Achieved through improvements in detection methods and reagents.
  5. Reduced sample volume requirements: Allowing for testing with smaller sample sizes.
  6. Customization and flexibility: Allowing researchers to tailor assays to their specific needs.

These advancements contribute to the development of more sensitive, specific, and efficient ELISA technologies for various applications in research, diagnostics, and drug development.

Schematic flowchart of indirect ELISA


Gentaur offers Western blot tests for the detection of HIV and Cysticercosis. The HIV Western blot test is designed to detect antibodies to HIV-1 and HIV-2 in human serum, plasma, or blood. It is used as a confirmatory test following a positive result from an initial HIV screening test.

The Cysticercosis Western blot test is used for the qualitative detection of antibodies to Taenia solium in human serum, plasma, or cerebrospinal fluid. This test is valuable for confirming a diagnosis of cysticercosis, a parasitic infection caused by the larvae of T. solium.